GEOVAX LABS, INC. (GOVX) - Description of business

Company Description

GeoVax Labs, Inc. focuses on developing vaccines that prevent and fight human immunodeficiency virus (HIV) infections, which result in acquired immunodeficiency syndrome (AIDS). The company?s ongoing research and development programs are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent or control infection of individuals who are exposed to the HIV virus; and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus. GeoVax Labs? preventative vaccine candidate is in a Phase IIa clinical trial. In addition to its clinical development program for its vaccine candidates, the company is conducting pre-clinical research on the impact of adding adjuvants (immune system stimulants) to the DNA priming component of its vaccine. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.